Darzalex (daratumumab) And Hepatitis B Virus Reactivation

DARZALEX Recall Summary DARZALEX (daratumumab), a cancer treatment drug distributed across Canada, is being recalled due to the risk of hepatitis B virus reactivation in patients who carry the virus. This means patients with inactive hepatitis B infection could experience a reactivation of the virus while taking this medication. The recall affects all patients in Canada who have received or may receive this drug.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2019-03-25

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/2541cd42-b282-450e-b478-d1af63a6b352